So Far This Year, bluebird bio Inc. (BLUE) Reached A New High 4 times

As of Thursday close, bluebird bio Inc.’s (NASDAQ:BLUE) stock was down -$0.18, moving down -4.04 percent to $4.28. The average number of shares traded per day over the past five days has been 24,347,621 shares. 4 times new highs have been achieved over the past 5 days, with a $0.80 gain in that time frame. In the last twenty days, the average volume was 12,825,875, while in the previous 50 days, it was 6,475,870.

Since last month, BLUE stock rose 27.76%. Shares of the company fell to $2.87 on 06/02/22, the lowest level in the past month. A 52-week high of $21.42 was reached on 01/04/22 after having rallying from a 52-week low of $2.87. Since the beginning of this year, BLUE’s stock price has dropped by -57.16% or -$5.71, and marked a new high 2 times. However, the stock has declined by -80.02% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


bluebird bio Inc. (BLUE) last reported insider trading activity 21 days ago on Jun 03. Klima Thomas J, the Chief Commercial Officer of the company, disposed of 3,753 shares for $3.07 on Jun 03. It resulted in a $11,535 divestment by the insider. Whitten Jessica sold 279 shares at an average price of $9.64 on Jan 11. The insider now owns 49,413 shares following the transaction. On Jan 11, President and CEO Obenshain Andrew sold 4,683 shares at $9.64 apiece. The transaction was valued at $45,156.

Valuation Metrics

The stock’s beta is 1.51. Besides these, the trailing price-to-sales (P/S) ratio of 55.91, the price-to-book (PB) ratio of 1.20.

Financial Health

Based on annual data, BLUE earned -$35.2 million in gross profit and brought in $3.66 million in revenue.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BLUE’s revenue fell -449.23% to -$35.88 million during the quarter, while net income inched up to $1.95 million. While analysts expected bluebird bio Inc. to report -$1.39 quarterly earnings, the actual figure was -$1.66 per share, beating the consensus estimate by -19.40%. During the quarter, the company generated -$119.33 million in EBITDA. The liabilities of bluebird bio Inc. were 227.81 million at the end of its most recent quarter ended March 30, and its total debt was $110.34 million. The value of shareholders’ equity is $71.45 million.

Technical Picture

This quick technical analysis looks at bluebird bio Inc.’s (BLUE) price momentum. With a historical volatility rate of 181.30%, the RSI 9-day stood at 61.43% on 23 June.

With respect to its five-day moving average, the current bluebird bio Inc. price is up by +22.99% percent or $0.80. At present, BLUE shares trade +30.89% above its 20-day simple moving average and -44.56% percent below its 100-day simple moving average. However, the stock is currently trading approximately -10.27% below its SMA50 and -76.74% below its SMA200.

Stochastic coefficient K was 43.45% and Stochastic coefficient D was 35.58%, while ATR was 0.68. Given the Stochastic reading of 42.85% for the 14-day period, the RSI (14) reading has been calculated as 58.02%. As of today, the MACD Oscillator reading stands at 0.46, while the 14-day reading stands at 0.70.

Analyst Ratings

bluebird bio Inc. downgraded its rating on bluebird bio Inc. (NASDAQ: BLUE) to a Market perform in a note to investors on April 06, 2022. The analysts firm previously had an Outperform rating on the stock.bluebird bio Inc. (BLUE) has been rated Underweight by analysts. According to 3 brokerage firms, BLUE is a sell, and 9 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate bluebird bio Inc. stock as buy, with 0 recommending it as overweight.

With a median target price of $8.00, the current consensus forecast for the stock is $2.00 – $14.00. Based on these forecasts, analysts predict bluebird bio Inc. (BLUE) will achieve an average price target of $6.88.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam